Aurinia Pharmaceuticals (NASDAQ:AUPH) Stock Price Up 11% – Should You Buy?

Aurinia Pharmaceuticals Inc. (NASDAQ:AUPH) (TSE:AUP) shares were up 11% during mid-day trading on Thursday . The company traded as high as $8.43 and last traded at $8.35. Approximately 1,352,715 shares traded hands during trading, a decline of 15% from the average daily volume of 1,591,148 shares. The stock had previously closed at $7.52.

Wall Street Analyst Weigh In

Several equities research analysts have recently weighed in on the stock. Cantor Fitzgerald reiterated an “overweight” rating and set a $10.00 target price on shares of Aurinia Pharmaceuticals in a research note on Monday, September 16th. HC Wainwright reissued a “buy” rating and issued a $13.00 target price on shares of Aurinia Pharmaceuticals in a report on Friday, September 6th. One equities research analyst has rated the stock with a hold rating and four have given a buy rating to the company. Based on data from MarketBeat, the stock presently has an average rating of “Moderate Buy” and a consensus target price of $10.00.

Aurinia Pharmaceuticals Stock Performance

The stock’s 50-day moving average is $7.07 and its 200 day moving average is $6.07. The stock has a market cap of $1.22 billion, a price-to-earnings ratio of -24.26 and a beta of 1.45. The company has a debt-to-equity ratio of 0.18, a current ratio of 5.33 and a quick ratio of 4.82.

Institutional Trading of Aurinia Pharmaceuticals

Several hedge funds have recently modified their holdings of AUPH. China Universal Asset Management Co. Ltd. raised its position in Aurinia Pharmaceuticals by 63.7% in the third quarter. China Universal Asset Management Co. Ltd. now owns 27,502 shares of the biotechnology company’s stock worth $202,000 after acquiring an additional 10,700 shares in the last quarter. CWM LLC grew its stake in shares of Aurinia Pharmaceuticals by 247.7% during the 3rd quarter. CWM LLC now owns 11,483 shares of the biotechnology company’s stock worth $84,000 after purchasing an additional 8,180 shares during the period. Handelsbanken Fonder AB increased its holdings in shares of Aurinia Pharmaceuticals by 13.2% in the 3rd quarter. Handelsbanken Fonder AB now owns 60,700 shares of the biotechnology company’s stock valued at $445,000 after purchasing an additional 7,100 shares in the last quarter. SG Americas Securities LLC lifted its stake in shares of Aurinia Pharmaceuticals by 4,307.9% in the third quarter. SG Americas Securities LLC now owns 547,727 shares of the biotechnology company’s stock valued at $4,015,000 after purchasing an additional 535,301 shares during the period. Finally, Stonepine Capital Management LLC purchased a new stake in Aurinia Pharmaceuticals during the second quarter worth about $1,713,000. 36.83% of the stock is owned by institutional investors and hedge funds.

Aurinia Pharmaceuticals Company Profile

Aurinia Pharmaceuticals Inc, a commercial-stage biopharmaceutical company, focuses on developing and commercializing therapies to treat various diseases with unmet medical need in the United States. It offers LUPKYNIS for the treatment of adult patients with active lupus nephritis. It has a collaboration and license agreement with Otsuka Pharmaceutical Co, Ltd.